Echinacea Species and Alkamides Inhibit Prostaglandin E2 Production in RAW264.7 Mouse Macrophage Cells by LaLone, Carlie A. et al.
Food Science and Human Nutrition Publications Food Science and Human Nutrition
2007
Echinacea Species and Alkamides Inhibit
Prostaglandin E2 Production in RAW264.7 Mouse
Macrophage Cells
Carlie A. LaLone
Iowa State University
Kimberly D.P. Hammer
Iowa State University
Lankun Wu
Iowa State University
Jaehood Bae
Iowa State University
Norma Leyva
Iowa State University
See next page for additional authors
Follow this and additional works at: http://lib.dr.iastate.edu/fshn_ag_pubs
Part of the Agronomy and Crop Sciences Commons, Cell Biology Commons, Chemistry
Commons, Food Science Commons, Genetics Commons, Horticulture Commons, Human and
Clinical Nutrition Commons, Pharmacology Commons, and the Statistics and Probability
Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
fshn_ag_pubs/21. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Food Science and Human Nutrition at Digital Repository @ Iowa State University. It has
been accepted for inclusion in Food Science and Human Nutrition Publications by an authorized administrator of Digital Repository @ Iowa State
University. For more information, please contact digirep@iastate.edu.
Authors
Carlie A. LaLone, Kimberly D.P. Hammer, Lankun Wu, Jaehood Bae, Norma Leyva, Yi Liu, Avery K.S. Solco,
George A. Kraus, Patricia A. Murphy, Eve S. Wurtele, Ok-Kyung Kim, Kwon II Seo, Mark P. Widrlechner, and
Diane F. Birt
This article is available at Digital Repository @ Iowa State University: http://lib.dr.iastate.edu/fshn_ag_pubs/21
Echinacea Species and Alkamides Inhibit Prostaglandin E2
Production in RAW264.7 Mouse Macrophage Cells
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The Center for Research on Dietary Botanical Supplements, Interdepartmental Genetics Graduate
Program, Department of Genetics, Development, and Cell Biology, Department of Chemistry,
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Inhibition of prostaglandin E2 (PGE2) production in lipopolysaccharide-stimulated RAW264.7 mouse
macrophage cells was assessed with an enzyme immunoassay following treatments with Echinacea
extracts or synthesized alkamides. Results indicated that ethanol extracts diluted in media to a
concentration of 15 íg/mL from E. angustifolia, E. pallida, E. simulata, and E. sanguinea significantly
inhibited PGE2 production. In further studies, PGE2 production was significantly reduced by all
synthesized alkamides assayed at 50 íM, by Bauer alkamides 8, 12A analogue, and 14, Chen
alkamide 2, and Chen alkamide 2 analogue at 25 íM and by Bauer alkamide 14 at 10 íM. Cytotoxicity
did not play a role in the noted reduction of PGE2 production in either the Echinacea extracts or
synthesized alkamides. High-performance liquid chromatography analysis identified individual
alkamides present at concentrations below 2.8 íM in the extracts from the six Echinacea species
(15 íg/mL crude extract). Because active extracts contained <2.8 íM of specific alkamide and the
results showed that synthetic alkamides must have a minimum concentration of 10 íM to inhibit
PGE2, it is likely that alkamides may contribute toward the anti-inflammatory activity of Echinacea in
a synergistic or additive manner.
KEYWORDS: Echinacea purpurea; Echinacea angustifolia; Echinacea pallida; Echinacea tennesseensis;
Echinacea simulata; Echinacea sanguinea; anti-inflammatory; cytotoxicity
INTRODUCTION
The use of Echinacea as a medicinal herb is prominent in
the United States, with sales encompassing approximately 10%
of the total U.S. market in botanical supplements (1). With the
increasing popularity of Echinacea, it is important to identify
its active constituents and determine extraction methods that
yield the proper doses of active constituents to elicit the desired
medicinal effect. Three species, E. purpurea, E. angustifolia,
and E. pallida, are commonly used in current botanical
preparations (medicinal species). The use of these medicinal
species originated from Native American peoples who utilized
Echinacea roots, aboveground parts, or a combination of both
as treatments for different ailments ranging from toothache to
rheumatism and as an antidote for poisons and venoms (2).
Four classes of active compounds have been identified within
Echinacea, yielding different chemical profiles among its nine
species (3). It has been hypothesized that alkamides, caffeic
acid derivatives, polysaccharides, and glycoproteins are the
classes of compounds responsible for the bioactivity of Echina-
cea (4). Echinacea purpurea contains alkamides, caffeic acid
esters (in particular cichoric acid), polysaccharides, and poly-
acetylenes, whereas in Echinacea pallida alkamides are mostly
absent and the most abundanat caffeic acid ester is echinacoside
(5). Furthermore, levels of constituents vary during growth and
across development (3, 5).
The chemical diversity these plants exhibit has made it
difficult for researchers to determine if Echinacea can be
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effective in treating colds and other respiratory infections (6).
Inconsistent results have been obtained from several placebo-
controlled studies designed to determine whether Echinacea
preparations were effective in the prevention of the common
cold and other upper respiratory infections. These conflicting
results were perhaps due to the use of different species and plant
parts, different preparations and doses, inconsistent times of
treatment initiation, and different virus types and doses (5, 6).
Some studies revealed a shorter duration of cold symptoms after
Echinacea treatment in comparison to placebo (7, 8), whereas
others showed no significant differences between treatment and
placebo groups (9, 10). Although the controversy regarding
efficacy continues, studies are accumulating that indicate
Echinacea may have antiviral, antioxidant, and anti-inflamma-
tory properties, making it a very promising medicinal botanical
(4, 11, 12).
Alkamides, also known as alkylamides, are a major group of
lipophilic, bioactive phytochemicals found abundantly in certain
species of Echinacea. Evidence indicates that alkamides possess
anti-inflammatory properties because they have been shown to
significantly reduce nitric oxide production in lipopolysaccharide
(LPS) stimulated RAW264.7 macrophages (12). Thus, much
attention is being directed toward alkamides to better understand
their potential use as anti-inflammatory agents as well as how
they interact with other constituents found in Echinacea (12).
Prostaglandin E2 (PGE2) is a critical inflammatory mediator
that is produced through the arachidonic acid cascade. Two
cyclooxygenase isoforms, COX-1 and COX-2, catalyze the
reaction converting arachidonic acid, released by phospholipase
A, to PGE2. LPS is a common endotoxin used to stimulate
macrophage cells to produce PGE2, mimicking an inflammatory
response in vitro (13). The use of RAW264.7 mouse macro-
phage cells has been established as a reliable cell model for
purposes of identifying anti-inflammatory activity (12).
The purpose of our study was to compare the bioactivities
of species of Echinacea and assess levels of variability on the
basis of repeat extractions and different harvest years. It was
also important to determine whether specific alkamides play a
clear role in the anti-inflammatory properties of six Echinacea
species. To this end, we have conducted (to our knowledge)
the first large-scale screen of nine synthesized alkamides found
in Echinacea, three synthesized analogues, two of Bauer
alkamide 12 (14) and one of Chen alkamide 2, and one
synthesized isomer of Chen alkamide 1 (12) for their ability to
reduce LPS-stimulated PGE2 production.
MATERIALS AND METHODS
Plant Material and Extraction. Plant samples were provided by
Frontier Natural Products Co-op (FNPC, Norway, IA) and the North
Central Regional Plant Introduction Station (NCRPIS, Ames, IA) of
the Agricultural Research Service of the U.S. Department of Agriculture.
The FNPC supplied E. purpurea, which had been harvested during its
budding stage in Bulgaria in 1999, where it was air-dried and, in 2001,
shipped to FNPC. Roots of plants representing the following 10
Echinacea accessions were obtained from the NCRPIS, where they were
harvested in October 2003, November 2004, and November 2005:
cultivated populations of E. purpurea (Ames 28189), E. angustifolia
(Ames 28187), and E. pallida (Ames 28188), all originally acquired
from Johnny’s Selected Seeds (Winslow, ME), and wild populations
of E. purpurea (PI 631307 and PI 633665), E. angustifolia (PI 631285),
E. pallida (PI 631293), E. simulata (PI 631251), E. sanguinea (PI
633672), and E. tennesseensis (PI 631250). Information about the
specific provenance of all accessions obtained from the NCRPIS is
available on the Germplasm Resources Information Network database
at http://www.ars-grin.gov/npgs/acc/acc_queries.html. Roots were har-
vested, and the plant material was prepared for storage by drying for
8 days at 38 °C in a forced-air dryer with constant humidity. The dried
material was ground with a 40-mesh screen and stored at -20 °C until
extraction. Extractions were made by using 6 g of dried Echinacea
root per population.
Extracts were prepared by one of two methods, either the Soxhlet
method (6 h) or room temperature shaking (24 h). Solvents ranging in
hydrophobicity were used for extraction, consisting of ethanol (70, 95,
or 100%), water, chloroform (100%), hexane (100%), or sequential
extractions. Sequential extractions were performed by extraction first
with chloroform (70, 95, or 100%) or hexane (70%), removal of the
solvent, and then evaporation. The residue plant material was re-
extracted with ethanol. FNPC plant material was extracted with either
100% ethanol using the Soxhlet method (heating solvent to its boiling
point) or shaking with 70% ethanol at room temperature. The Soxhlet
method was determined to yield optimal material and was therefore
used to extract NCRPIS Echinacea material with 95% ethanol. Upon
complete drying of the extract by evaporation, the residue was
redissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis,
MO) at the highest concentration that was soluble. Extracts were stored
at -30 °C in the dark and used as stock solutions.
Endotoxin. Echinacea extracts from NCRPIS were all screened for
endotoxin by using the Limulus Amebocyte Lysate Test (BioWhittaker,
Inc., Walkersville, MD) according to the manufacturer’s specifications
for a microplate assay. After accounting for the dilutions used in the
PGE2 assay, the range of endotoxin levels presented to RAW264.7
macrophage cells varied from undetectable to 0.0082 EU/mL. At these
levels the endotoxin found was well below the required amount needed
(>5 EU/mL) to induce the production of PGE2 in RAW264.7 cells
(15).
Cell Culture. RAW264.7 mouse monocyte/macrophage cells were
obtained from American Type Culture Collection (catalog no. TIB-71,
Manassas, VA) and cultured as described by Hammer et al. (15). NIH/
3T3 mouse fibroblast cells, SW480 human colon cancer cells, and
HaCaT human skin cancer cells were cultured according to procedures
described by Schmitt et al. (16).
Alkamide Synthesis. Chemical synthesis of Bauer (14) and Chen
alkamides (12) were conducted according to the procedures outlined
by Wu et al. (17), Kraus and Bae (18), and the thesis of Jaehoon Bae
(Iowa State University, 2006) (19). The synthesized alkamides allowed
for the comparison of activity of purified alkamide constituents, both
those found in Echinacea and derivatives of those alkamides.
Measurement of Prostaglandin E2. Echinacea extract and alkamide
treatments of RAW264.7 cells and the PGE2 enzyme immunoassay
(EIA) used to detect the amount of PGE2 (GE Biosciences, Piscataway,
NJ) were previously described by Hammer et al. (15). Preparations of
E. purpurea extracts from FNPC were extracted with several solvents
including Soxhlet EtOH, room temperature (RT) EtOH, Soxhlet
chloroform, and Soxhlet hexane, as well as sequential Soxhlet extracts
with chloroform/EtOH and hexane/EtOH. Initial screens for PGE2
production comparing different solvents resulted in significant increases
in PGE2 levels with all solvents except Soxhlet EtOH, RT EtOH, and
Soxhlet chloroform in the absence of LPS. These results as well as the
common use of ethanol in herbal supplements guided our laboratory
to use Soxhlet EtOH extract preparations in our assays. Also, Soxhlet
EtOH extracts performed optimally in our assays, compared to water
extracts that generally had higher endotoxin contamination (data not
shown). Work conducted by Bauer et al. (14) supports the use of ethanol
extractions of Echinacea, which allow for the enrichment of lipophilic
compounds including the ethanol-soluble alkamides (20). Baicalein
(5,6,7-trihydroxyflavone), found in the Chinese medicinal herb Scutel-
laria baicalensis, and quercetin (3,5,7,3′4′-pentahydroxy flavon), present
in the aboveground parts of E. purpurea (21), are flavonoids that are
known to exert anti-inflammatory as well as antioxidant effects and
were used as positive controls for the PGE2 assay due to these properties
(baicalein was synthesized by Iowa State University, and quercetin was
purchased from Sigma-Aldrich).
Cytotoxicity. Celltiter96 Aqueous One Solution Cell Proliferation
Assay (Promega Corp., Madison, WI) was used to analyze cytotoxicity
following a modified version of Schmitt et al.’s protocol (16).
RAW264.7 cells were plated into 48-well plates at a density of 0.5 
105cells/well and incubated at 37 °C for 24 h before treatment.
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Treatments were prepared by diluting the 6 g of Echinacea extract or
alkamide in DMSO and then further diluting with media to the
concentrations specified under Results. The stock extracts diluted to
1% of the total treatment concentration (0.1% if shown to be cytotoxic
at 1%) or synthesized alkamide diluted to 0.1% of the total treatment
concentration were randomly assigned to plate wells and incubated for
24 h (8 h if shown to be cytotoxic at 24 h) along with pure media and
DMSO as solvent controls. Ursolic acid, a triterpenoid known for its
cytotoxic activities (22), was used as a positive control at concentrations
of 10, 30, and 50 íM, yielding significant cytotoxicity (p < 0.0001) at
the two higher concentrations. Following the 24 h incubation period,
treatment solutions were removed, and fresh media and Celltiter96 dye
were added for 195 min, which was found to be the optimal incubation
time for this study. The metabolized dye solutions were then transferred
to 96-well plates for absorbance measurement at 562 nm. The number
of viable cells for each treatment was compared to the media + DMSO
control, and the percent of control survival was determined for each
extract or alkamide.
High-Performance Liquid Chromatography Analysis. The HPLC
method was described in previously published work (17, 23). Briefly,
into 320 íL of Echinacea extracts were added 40 íL (1 mg/mL) of
N-isobutylundeca-2-ene-8,10-diynamide (C15H21O2) and 40 íL (1 mg/
mL) of 3,5-dimethoxy-4-hydroxycinnamic acid (C11H12O5) as internal
standards for quantification of lipophilic metabolites and hydrophilic
metabolites, respectively. Fifteen microliters of each extract was injected
into a HPLC. The instrumentation and solvent system for HPLC
separation were the same as those previously published (23). For
compound identification, Bauer alkamides 8/9, cichoric acid, echina-
coside, caftaric acid, and cynarin were purchased from Phytolab
(Vestenbergsgreuth, Germany); chlorogenic acid was purchased from
Sigma-Aldrich; and Bauer alkamides 2 and 10-14 and ketones 20-
22 were synthesized (17, 18). Peaks were identified according to
retention time and mass spectra obtained from LC-MS and/or GC-MS.
In the absence of standards, Bauer alkamides 1, 3, 4, 5, 7, 15, 16, and
17 and ketone 24 were identified by HPLC fractionation coupled with
GC-MS analysis. Specifically, eluted HPLC fractions were collected
and subsequently subjected to GC-MS analysis; six replicate runs were
carried out, and appropriate peaks were pooled to ensure sufficient yield
of each alkamide. Compounds contained in each pooled fraction were
identified by comparing their recorded mass spectra and online UV
spectra with those from published literature (24). Compounds were
quantified on the basis of internal standards. The percent repeatability
and limits of detection for HPLC quantification of Bauer alkamides 2,
8/9, 10, 11, 12, 13, and 14, ketones 20, 21, and 22, caftaric acid,
chlorogenic acid, cynarin, echinacoside, and cichoric acid with reference
standards range between 1.64 and 2.86% and between 0.02 íg/mL and
0.16 íg/mL, respectively. The repeatability was determined by analyz-
ing repeated injections of the standard solution (n ) 6). The standard
deviation values of the repeatability are <3%, illustrating the precision
of the HPLC method.
Statistical Analysis. For both PGE2 data and cytotoxicty data, in
separate analyses, the results were log transformed and normalized to
the media + DMSO control allowing for the combination of treatments
on different plates. Cytotoxicity was analyzed by using a mixed model,
in which the plate was considered a random effect. A two-way ANOVA
was used followed by a Dunnett multiple-comparison test (25) for PGE2
and cytotoxicity assays. Data are represented as percent of media +
DMSO control set to 100%. Statistical significance was defined as p
< 0.05, and 95% confidence intervals were used. PGE2 data from
alkamide treatments were analyzed the same as the Echinacea extracts,
except data are expressed as mean percent reduction as compared to
media + DMSO control set at 0%. The statistical program used for all
analyses was SAS 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
Extracts from Echinacea Species Inhibit PGE2 Production.
To assess the anti-inflammatory properties of six Echinacea
species, Soxhlet EtOH extracts were initially screened in
RAW264.7 cells at their highest concentration (ranging in final
concentrations from 21 to 53 íg/mL) for their ability to reduce
PGE2 levels after stimulation with LPS (Figure 1). E. angus-
tifolia and E. pallida extracts from NCRPIS and Johnny’s
Selected Seeds significantly inhibited PGE2 levels at concentra-
tions above 21 íg/mL. Neither E. purpurea accession screened
in Figure 1 significantly inhibited PGE2 (28 íg/mL of extract
from NCRPIS and 24 íg/mL of extract from Johnny’s Selected
Seeds). Treatments analyzed without the addition of LPS
reduced PGE2 levels in E. purpurea and E. angustifolia
compared to media + DMSO control. Baicalein and quercetin
were included as positive controls for every PGE2 experiment.
After initial screening, the extracts were diluted to 15 íg/mL
in DMSO for activity comparisons across species. There was
no significant difference among harvest year, accession, or
Soxhlet EtOH extract preparation for E. purpurea (six extracts),
E. angustifolia (four extracts), E. pallida (four extracts), E.
sanguinea (two extracts), E. simulata (two extracts), or E.
tennesseensis (two extracts), which allowed data to be pooled.
Of the three medicinal species, E. angustifolia and E. pallida
significantly inhibited PGE2 levels (p < 0.05) (Figure 2). Three
nonmedicinal species were also screened for anti-inflammatory
activity. E. sanguinea and E. simulata significantly reduced
PGE2 production (p < 0.001 and p < 0.05, respectively). Of
the six species being compared in this study, E. purpurea and
E. tennesseensis showed the least activity in this assay. Of the
four active species that reduced PGE2 production, none was
significantly more active than the other when confidence
intervals across species were compared.
Screening for Cytotoxicity of Extracts of Echinacea
Species. To determine whether any of the NCRPIS Soxhlet
EtOH extracts had the ability to arrest metabolic activity in
RAW264.7 macrophage cells and to provide further evidence
that the observed PGE2 reduction with treatment of Echinacea
extracts was not due to cytotoxicity, a parallel study using the
Celltiter96 Aqueous One Solution Cell Proliferation Assay was
conducted. Table 1 displays an initial screening of each extract
at a 1% concentration of extract diluted in media for a 24 h
incubation. This initial screening used 10-fold higher concentra-
tions than those used in the PGE2 screens. All extracts showed
significant cytotoxicity (p < 0.0001), with 25-72% survival
at the 1% concentration (ranging from 240 to 1102 íg/mL of
extract) and 24 h of incubation.
Figure 1. Inhibition of PGE2 production by Soxhlet ethanol extracts of
medicinal species of Echinacea treated at their highest concentration (6
g of extract diluted initially in DMSO and then prepared as 0.1% of the
media). Each bar represents three replicates ± standard deviation. Dry
material was obtained from the 2005 harvests grown by NCRPIS. Johnny’s
Selected Seeds accessions are denoted JS on the graph, and PI is
indicative of accessions from NCRPIS. /, p < 0.05, and //, p < 0.001,
for comparison of extract to control. Media + DMSO and media + DMSO
+ LPS treatments are represented by gray and black bars, respectively.
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All extracts cytotoxic at the 1% concentration were screened
again at the 0.1% concentration of extract diluted in media
(concentrations ranging from 24 to 110 íg/mL of extract) after
a 24 h incubation. Results in Table 1 show that only one extract
of E. pallida from the 2003 harvest (PI 631293) remained
significantly cytotoxic at the 0.1% dilution after a 24 h
incubation, but when this same extract was screened for
cytotoxicity at the same dilution after an 8 h incubation,
equivalent to the incubation period in the PGE2 assay, no
significant cytotoxicity remained (p ) 0.9968). The screens
conducted at 0.1% concentration matched concentrations used
in PGE2 screens.
Cytotoxicity Screen of FNPC E. purpurea Extracts. Vi-
ability of NIH/3T3 mouse fibroblast cells, SW480 human colon
cancer cells, and HaCaT human skin cancer cells treated with
FNPC E. purpurea extracts was assessed by using the Celltiter96
Aqueous One Solution Cell Proliferation Assay. Cytotoxicity
was not observed in any of the FNPC E. purpurea extracts at
a concentration of 10 íg/mL. Significant cytotoxicity was
observed only at high concentrations (g95 íg/mL of extract),
with the exception of one extract showing significant cytotox-
icity (p < 0.01) at 39 íg/mL [(RT) 70% hexane 24 h, SW480
cells]. This extract protocol was not used in further studies.
Results from these data indicate that all other extracts prepared
from FNPC E. purpurea showed little or no cytotoxicity in the
three different cell lines at concentrations of <100 íg/mL.
Synthesized Alkamides from Echinacea Species Inhibit
PGE2 Production. To further probe the inhibition of PGE2
production in RAW264.7 cells observed with treatments of
Echinacea extracts, another PGE2 screening was conducted on
chemically synthesized alkamides, one of Echinacea’s major
classes of bioactive constituents. Data from Table 2 show that
all of the synthesized alkamides screened significantly inhibited
the production of PGE2 (p < 0.001) at 50 íM. At 25 íM, Bauer
alkamide 8, Bauer alkamide 12A analogue, Bauer alkamide 14,
Chen alkamide 2, and Chen alkamide 2 analogue significantly
reduced PGE2 levels (p < 0.05). Only Bauer alkamide 14
significantly inhibited PGE2 production at 10 íM (p < 0.05).
A subsequent PGE2 EIA experiment was conducted to attempt
to determine if PGE2 could inhibit at concentrations of <10
Figure 2. Inhibition of PGE2 production by extracts of three medicinal and three nonmedicinal species of Echinacea (diluted to 15 íg/mL of extract in
DMSO) obtained from NCRPIS with different harvest dates and accession numbers. Each species mean is represented by a bar (two to six replicates
each), and variability is represented as 95% confidence intervals of the mean. Treatments analyzed without the addition of LPS did not affect PGE2
levels with values for PGE2 as percent of media + DMSO control <20% (data not shown). One E. angustifolia extract, from the 2004 harvest, treated
without LPS, was excluded from the analysis on the basis of the optical density data point being outside the standard curve. /, p < 0.05, and //, p <
0.001, for comparison of extract to control (media + DMSO + LPS).
Table 1. Cytotoxicity Screening of Soxhlet EtOH Extracts from Six Echinacea Speciesa
species
harvest
year accession
1% concn
(íg/mL)
% survival (95% CI),
p value
0.1% concn
(íg/mL)
% survival (95% CI),
p value
E. angustifolia 2005 JS 535 71 (53, 97), 0.0166 54 92 (74, 116), 0.9792
E. purpurea 2003 PI 633665 518 65 (48, 88), 0.0004 52 104 (79, 139), 1.0000
E. purpurea 2005 JS 240 72 (53, 97), 0.0181 24 105 (78, 139), 1.0000
E. pallida 2003 PI 631293 579 68 (50, 92), 0.0021 58 75 (56, 99), 0.0365
E. pallida 2005 JS 359 32 (26, 40), <0.0001 36 133 (100, 177), 0.0457
E. tennesseensis 2003 PI 631250 950 66 (53, 83), <0.0001 95 112 (84, 149), 0.9431
E. simulata 2003 PI 631251 1101 25 (20, 32), <0.0001 110 102 (77, 136), 1.0000
E. simulata 2004 PI 631251 1102 25 (20, 30), <0.0001 110 110 (83, 146), 0.9817
E. sanguinea 2003 PI 633672 834 36 (28, 45), <0.0001 83 93 (74, 116), 0.9874
E. sanguinea 2004 PI 633672 672 34 (27, 43), <0.0001 67 96 (73, 128), 1.0000
a Cytotoxicity (percent of control compared to vehicle control-treated RAW264.7 cells) of Echinacea extracts screened via the Celltiter96 Aqueous One Solution Cytotoxicity
assay (n ) 3−4). PI numbers denote NCRIPS accessions, whereas JS denotes accessions from Johnny’s Selected Seeds. All extract stocks were prepared from 6 g of
dried root plant material by Soxhlet 95% EtOH extraction, were diluted in DMSO and included as 1% of the cell culture medium or, if significantly cytotoxic at 1%, diluted
to 0.1%. The treatment concentration listed for each extract (íg/mL) is the amount of extract residue used in the assay after extraction and dilution in DMSO. p value for
comparison of extract treatment to control (media + DMSO). Boldface p values represent statistical significance with p < 0.05.
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Table 2. Inhibition of PGE2 Production by Alkamides
*p value for comparison of alkamide treatment to control (media + DMSO + LPS). Boldface p values represent statistical significance as defined as a p value of <0.05. Media + DMSO
+ LPS control set to 0% reduction. There was no difference between extracts in medium alone having an overall percent reduction (95% CI) of 2 (−27, 24) and media + DMSO controls.
Baicalein (6 íM) and quercetin (10 íM) were used as positive controls having overall percent reductions (95% CI) of 72 (62, 79) and 88 (85, 91), respectively. All samples in the table
are treated with 1 íg/mL LPS. Alkamide treatments did not affect PGE2 levels without LPS treatment (data not shown). Bauer alkamides are found in Bauer et al. (14) and **Chen
alkamides in Chen et al. (12). Isomers and analogues of naturally occurring alkamides are indicated with the + symbol and have not been detected to date from Echinacea species
extracts in our laboratories.
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íM. After storage of Bauer alkamide 14 at -24 °C for 1 year,
HPLC analysis indicated that it had degraded to 31% of the
original concentration. The concentrations screened for PGE2
production were 3.1 and 0.230 íM, and Bauer alkamide 14 was
unable to significantly inhibit PGE2 at these concentrations (data
not shown).
Screening for Cytotoxicity of Synthesized Alkamides.
Parallel cytotoxicity screenings were carried out for the alka-
mides by using the Celltiter96 Aqueous One Solution Cell
Proliferation Assay in RAW264.7 mouse macrophage cells. The
alkamides were all screened at 50 íM for a 24 h incubation.
None of the 13 alkamides demonstrated any significant cyto-
toxicity (85-113% survival), indicating that cell death was not
a factor in the data obtained from the PGE2 screening (data not
shown).
HPLC Analysis of Echinacea Extracts at 15 íg/mL. HPLC
was performed with 15 íg/mL of Echinacea extracts from
NCRPIS to identify and analyze innate concentrations of known
constituents (Table 3). E. angustifolia, E. sanguinea, E.
purpurea, and E. tennesseensis contained greater quantities of
Bauer alkamides than of ketones or caffeic acid derivatives.
Bauer alkamides 3 and 8-13 were present in E. angustifolia at
concentrations of >0.1 íM, with Bauer alkamide 9 reaching
concentrations of 2.8 and 1.6 íM in the two extracts analyzed.
All accessions of E. sanguinea also contained Bauer alkamides
3, 8, 9, 12-14, and 17 at concentrations ranging from 0.16 to
1.15 íM. Two different accessions of E. purpurea (PI 63665
and PI 631307) were analyzed by HPLC and were found to
both contain similar alkamides, including Bauer alkamides 1-3
and 7-9 (>0.1 íM). Cichoric acid was present in one extract
of each accession from the 2003 harvest of E. purpurea. E.
tennesseensis (2003 and 2004 harvests) contained Bauer alka-
mide 12 at concentrations of >0.3 íM and Bauer alkamide 13
at concentrations of >0.6 íM. Two species, E. pallida and E.
simulata, were determined to possess greater amounts of ketones
than of alkamides. E. pallida had concentrations exceeding 0.1
íM for ketones 22 and 24. Ketone 22 was also present in E.
simulata extracts (>0.1 íM of ketone). Chen alkamide 1, Chen
alkamide 1 isomer, Chen alkamide 2 analogue, Bauer alkamide
12A analogue, and Bauer alkamide 12B analogue from Table
2 were not detected in this analysis, but may be present in
concentrations below the detection limits of our instrument.
Some alkamides, ketones, and caffeic acid derivatives were
present in only certain extracts within the species and are
identified in Table 3.
DISCUSSION
The results presented in this study demonstrate the inhibition
of PGE2 by several Echinacea species, which may be one
process contributing to the reported anti-inflammatory capabili-
ties of these herbs (12). All Soxhlet EtOH extracts from the six
species screened, when tested at their highest concentration,
reduced PGE2 levels, except E. purpurea. To compare inhibition
potential among these species, extracts were diluted to 15 íg/
mL in DMSO, with E. angustifolia, E. pallida, E. sanguinea,
and E. simulata significantly inhibiting the production of PGE2
in LPS-induced RAW264.7 mouse macrophage cells. E. pur-
purea extracts (15 íg/mL) did not significantly inhibit PGE2,
which was notable because many Echinacea supplements
Table 3. HPLC Analysis of Soxhlet EtOH Extracts of Echinacea Species (15 íg/mL)a
a The units for values in the table are all íM. The HPLC analysis identifies three main classes of constituents found in the species of Echinacea extracts (15 íg/mL
of extract) obtained from NCRPIS, namely, alkamides, ketones, and caffeic acid derivatives. Shaded cells identify compounds for which concentrations exceed 0.1 íM. Due
to the repeatability of our HPLC method, described under Materials and Methods, constituents are represented by an N ) 1; therefore, no statistical analysis was performed
on these data. Dashes represent values below instrumental detection limits. Structures and nomenclature of Bauer alkamides 2, 8, and 10−14 presented in the above table
were previously shown in Table 2, and other alkamides and ketones can be found in Bauer et al. (14). Structures of caffeic acid derivatives have previously been reported.
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contain E. purpurea as a major ingredient (21). Another
interesting finding was that variability between species was
greater than that observed between repeat extractions or harvest
years. Results obtained from screening Echinacea extracts in
RAW264.7 cells for cytotoxicity coincide with observations
from NIH/3T3 mouse fibroblast cells, SW480 human colon
cancer cells, and HaCaT human skin cancer cells, which showed
these extracts to be cytotoxic only at high concentrations (>240
íg/mL of extract).
Alkamides have become a major focus for researchers
studying Echinacea, due to their abundance in both aboveground
and underground parts of the plant in most species. Studies link
this class of compounds to a vast repertoire of immunomodu-
latory activities, including antiviral, antimicrobial, antibacterial,
and antioxidant as well as anti-inflammatory properties (26).
Alkamides may be best known through recent studies indicating
their ability to modulate the immune system, potentially, by
binding to the cannabinoid 2 receptor (CB2) (27). This receptor
has been shown to be expressed in many types of inflammatory
and immune-competent cells, and it has been suggested that
the CB2 receptor may play a part in inflammatory reactions
(28). Alkamides have been shown, through the use of CB1 and
CB2 antagonists and signal transduction pathway inhibitors, to
up-regulate TNF-R mRNA and increase cAMP, p38/MAPK,
and JNK signaling, as well as activate NF-kB through the CB2
receptor in human monocyte/macrophage cells (29).
Our results provide further support to previous studies
indicating that alkamides are key constituents found in Echina-
cea that possess anti-inflammatory properties. Our experiments
indicated that alkamides are consistent inhibitors of PGE2
production at a concentration of 50 íM, with selected alkamides
having the capability to significantly inhibit PGE2 levels at
concentrations of 25 íM or even 10 íM. Although many
alkamides have been identified, it is possible that undescribed
isomers as well as analogues of many of the known alkamides
may exist naturally in some of the Echinacea species, and on
the basis of our results, some of these may also be inhibitors of
inflammatory mediators. Cytotoxicity did not appear to con-
tribute to reduced PGE2 production by extracts or alkamides,
suggesting that the observed inhibition was a true inhibition of
PGE2 and not an artifact due to cell death. The data presented
strengthen the research indicating that alkamides present in
Echinacea contribute to immunomodulatory properties dealing
with regulation of inflammation (27).
Questions as to how alkamides act together and in concert
with other constituents arise from our HPLC analysis. Our data
identify alkamides present in crude Echinacea extracts at
concentrations below 2.8 íM, which is well under the 10 íM
concentration observed for inhibitory activity of PGE2 seen with
chemically synthesized Bauer alkamide 14. Regardless, several
of the crude extracts of Echinacea, containing a variety of
alkamides, ketones, and caffeic acid derivatives at low concen-
trations, were able to significantly inhibit PGE2 production. For
example, E. sanguinea extracts at 15 íg/mL, containing Bauer
alkamides 8 and 12-14, at higher concentrations than other
constituents present, showed the greatest inhibition of PGE2
among the species we evaluated, with a percent reduction of
59%, whereas none of these alkamides would be able to inhibit
PGE2 production alone at such low concentrations. Therefore,
we hypothesize that the noted inhibition of PGE2 and, by
extension, the anti-inflammatory properties found in Echinacea
extracts were not simply due to one constituent, but several
acting in a synergistic or additive manner. Synergism has been
reported previously between alkamides and caffeic acid deriva-
tives and their ability to inhibit the oxidation of low-density
lipoproteins, as an indicator of antioxidant activity (4). Our
HPLC analysis revealed no clear pattern of identifiable con-
stituents that led to the observed inhibition of PGE2 by extracts
from E. angustifolia, E. pallida, E. simulata, or E. sanguinea,
indicating that more research is needed to understand the
complex nature of interacting constituents within each species
and to determine mechanisms behind the identified PGE2
inhibition. A possible explanation for the resemblance of
constituents found in E. pallida and E. simulata may be related
to the hypothesis that E. simulata is one of the diploid
progenitors of the tetraploid species, E. pallida (30). A PGE2
screening of synthesized ketones and caffeic acid derivatives
individually may lead to a better understanding of Echinacea’s
anti-inflammatory capabilities.
A study performed by Chen et al. (12) indicated that
alkamides had anti-inflammatory activity as measured by
inhibition of nitric oxide (NO) production in LPS-stimulated
RAW264.7 cells. NO is a pro-inflammatory mediator that was
significantly reduced by total alkamide (a mixture consisting
of several alkamides) ranging from 1.6 to 30 íg/mL. Chen et
al. (12) also examined individual alkamides and inhibition doses
that caused reduction of LPS-mediated NO production in
comparison to an LPS control. The ID50 for Bauer alkamide 2
was 54 íM, that for Bauer alkamide 8 was 24 íM, that for
Bauer alkamide 10 was 40 íM, that for Bauer alkamide 11 was
24 íM, that for Bauer alkamide 13 was 108 íM, that for Chen
alkamide 1 was 49 íM, and that for Chen alkamide 2 was 35
íM. The inhibition of NO measured by the ID50 corresponds
to our PGE2 data in that our results show significant inhibition
of another inflammatory mediator, PGE2, at 50 íM for all
alkamides screened, as well as Bauer alkamide 8 and Chen
alkamide 2 significantly inhibiting at 25 íM. Also, in that study
(12), cytotoxicity sufficient to cause 50% cell death was reported
for individual alkamides ranging in concentration from 50 to
217 íM. Only Bauer alkamide 11 showed 50% cell death at 50
íM in the Chen et al. study, which contradicts our results
showing Bauer alkamide 11 to produce 94% survival in the
Celltiter96 Aqueous One Solution Cell Proliferation Assay at
the same concentration. All other alkamides screened by Chen
et al. (12) were at concentrations higher than those screened by
our laboratory for cytotoxicity, perhaps accounting for the
cytotoxicity noted in their study.
Studies are providing convincing evidence that alkamides can
play important roles in the bioactivity observed in Echinacea
species, and questions about the bioavailability of this class of
constituents are still being answered. Alkamides have been
shown to be readily bioavailable through the Caco-2 cell
monolayer, more so than other active compounds, such as the
caffeic acid derivatives found in Echinacea (31). Another study
had previously supported these data by finding that (2E,4E,8Z,-
10Z)-N-isobutyldodeca-2,4,8,10-tetraenamide could be com-
pletely transported from the apical to the basolateral side of
the Caco-2 monolayer, with no significant metabolism occurring
(32). Results from a study investigating the metabolism of
natural and synthetic alkylamides from Echinacea by using
human liver microsomes determined that cytochrome P450
mediated epoxidation, hydroxylation, and dealkylation of alk-
ylamides occurred (33). A recent human study analyzed 11
human subjects for bioavailability of an oral administration of
a 60% ethanolic extract of E. angustifolia root, which was
known to contain six identified alkamides, showing that after
30 min one of the six alkamides, dodeca-2E,4E,8Z,10E/Z-
tetraenoic acid isobutylamide, appeared in plasma samples at
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10.88 ng/mL for a 2.5 mL dose (34). Another human study
analyzed nine volunteers who consumed tablets of 675 mg of
E. purpurea and 600 mg of E. angustifolia, after a high-fat
breakfast or after a fast, for alkamide content in their plasma
(35). Total 2,4-diene alkamides were found in the plasma from
the high-fat group with a maximum concentration ranging from
60 to 1137 ng/mL. Although it is becoming increasingly evident
that alkamides are bioavailable, more experimentation is war-
ranted to determine whether alkamides can exert anti-inflam-
matory or other immunomodulatory effects at the low concen-
tration of 10 íM, which was the lowest concentration found to
be bioactive in our PGE2 studies. Without more definitive
bioavailablility data, a difficulty arises in making assumptions
about alkamides’ anti-inflammatory properties based on cell
culture data.
In summary, this study indicates that Echinacea extracts may
be able to modulate inflammation through their inhibitory
activity on PGE2 production and that alkamides are possible
key constituents in the observed anti-inflammatory properties,
most likely acting additively or synergistically with other
constituents. Therefore, because innate concentrations of indi-
vidual alkamides found in crude extracts do not reach concen-
trations shown to have significant PGE2 inhibition capabilities
found from tests of pure, synthesized alkamides, it is clear that
the presence of individual alkamides alone cannot explain the
observed anti-inflammatory activity.
ABBREVIATIONS USED
E., Echinacea; PI, Plant Introduction; FNPC, Frontier Natural
Products Co-op; NCRPIS, North Central Regional Plant Intro-
duction Station; PGE2, prostaglandin E2; LPS, lipopolysaccha-
ride.
SAFETY
Organic solvents, such as hexane and chloroform used for
extractions, are toxic chemicals and should be properly handled
in a fume hood. LPS compounds are pyrogenic and should not
be inhaled or allowed to enter the bloodstream.
ACKNOWLEDGMENT
We thank all members of the Center for Research on Botanical
Dietary Supplements at Iowa State University and the University
of Iowa for their cooperation and ongoing advice in directing
the progress of this research. We give special thanks for the
gift of Echinacea plant material from Frontier Natural Products
Co-op (Norway, IA) as well as to Fredy Romero and members
of the Organic Agriculture Program and the NCRPIS at Iowa
State University (Ames, IA). We acknowledge Philip Dixon and
Man-Yu Yum for their statistical guidance as well as Zili Zhai
and Joan Cunnick for endotoxin analysis of the NCRPIS
extracts.
LITERATURE CITED
(1) Koenig, K.; Roehr, C. Does treatment with Echinacea purpurea
effectively shorten the course of upper respiratory tract infections
in children? Arch. Dis. Child. 2006, 91, 535-537.
(2) Borchers, A.; Keen, C.; Stern, J.; Gershwin, M. Inflammation
and Native American medicine: role of botanicals. Am. J. Clin.
Nutr. 2000, 72, 339-347.
(3) Harborne, J.; Williams, C. Phytochemistry of the genus Echina-
cea. In Echinacea The Genus Echinacea; Miller, S., Ed.; CRC
Press: Boca Raton, FL, 2004; pp 39, 55-71.
(4) Dalby-Brown, L.; Barsett, H.; Landbo, A.; Mayer, A.; Molgaard,
P. Synergistic antioxidative effects of alkamides, caffeic acid
derivatives, and polysaccharide fractions from Echinacea pur-
purea on in vitro oxidation of human low-density lipoproteins.
J. Agric. Food Chem. 2005, 53, 9413-9423.
(5) Upton, R.; Graff, A.; Swisher, D.; McGuffin, M.; Pizzorno, J.;
Prill, R. Echinacea pupurea Root: Echinacea purpurea (L.)
Moench. Standards of Analysis, Quality Control, and Therapeu-
tics. American Herbal Pharmacopoeia and Therapeutic Com-
pendium; Scotts Valley, CA, 2004; pp 1-53.
(6) Schoop, R.; Klein, P.; Suter, A.; Johnston, S. Echinacea in the
prevention of induced rhinovirus colds: a meta-analysis. Clin.
Ther. 2006, 28, 174-183.
(7) Schulten, B.; Bulitta, M.; Ballering-Bruhl, B.; Koster, U.; Schafer,
M. Efficacy of Echinacea purpurea in patients with a common
cold. A placebo-controlled, randomized, double-blind clinical
trial. Arzneimittelforschung 2001, 51, 563-568.
(8) Goel, V.; Lovlin, R.; Barton, R.; Lyon, M.; Bauer, R.; Lee, T.;
Basu, T. Efficacy of a standardized Echinacea preparation
(Echinilin) for the treatment of the common cold: a randomized,
double-blind, placebo-controlled trial. J. Clin. Pharm. Ther. 2004,
29, 75-83.
(9) Sperber, S.; Shah, L.; Gilbert, R.; Ritchey, T.; Monto, A.
Echinacea purpurea for prevention of experimental rhinovirus
colds. Clin. Infect. Dis. 2004, 38, 1367-1371.
(10) Yale, S.; Liu, K. Echinacea purpurea therapy for the treatment
of the common cold: a randomized, double-blind, placebo-
controlled clinical trial. Arch. Intern. Med. 2004, 164, 1237-
1241.
(11) Binns, S.; Hudson, J.; Merali, S.; Arnason, J. Antiviral activity
of characterized extracts from Echinacea spp. (Heliantheae:
Asteraceae) against Herpes simplex virus (HSV-1). Planta Med.
2002, 68, 780-783.
(12) Chen, Y.; Fu, T.; Tao, T.; Yang, J.; Chang, Y.; Wang, M.; Kim,
L.; Qu, L.; Cassady, J.; Scalzo, R.; Wang, X. Macrophage
activating effects of new alkamides from the roots of Echinacea
species. J. Nat. Prod. 2005, 68, 773-776.
(13) Patel, R.; Attur, M.; Dave, M.; Abramson, S.; Amin, A.
Regulation of cytosolic COX-2 and prostaglandin E2 production
by nitric oxide in activated murine macrophages. J. Immunol.
1999, 162, 4191-4197.
(14) Bauer, R.; Jurcic, K.; Puhlmann, J.; Wagner, H. Immunological
in ViVo and in Vitro examinations of Echinacea extracts. Arzneim.
Forsch./Drug Res. 1988, 38, 276-281.
(15) Hammer, K.; Hillwig, M.; Solco, A.; Dixon, P.; Delate, K.;
Murphy, P.; Wurtele, E.; Birt, D. Inhibition of PGE2 production
by anti-inflammatory Hypericum perforatum extracts and con-
stituents in RAW264.7 mouse macrophage cells. J. Agric. Food
Chem. 2007, 55, 7323-7331.
(16) Schmitt, L.; Liu, Y.; Murphy, P.; Birt, D. Evaluation of the light-
sensitive cytotoxicity of Hypericum perforatum extracts, frac-
tions, and pure compounds. J. Agric. Food Chem. 2006, 54,
2881-2890.
(17) Wu, L.; Bae, J.; Kraus, G.; Wurtele, E. Diacetylenic isobutyla-
mides of Echinacea: synthesis and natural distribution. Phy-
tochemistry 2004, 65, 2477-2484.
(18) Kraus, G.; Bae, J. Synthesis of N-(2-methylpropyl)-2E-undecene-
8,10-diynamide, a novel constituent of Echinacea angustifolia.
Tetrahedron Lett. 2003, 44, 5505-5506.
(19) Bae, J. Synthesis of the natural compounds in Echinacea. Thesis,
Iowa State University, 2006.
(20) Bone, K. Echinacea: Quality, uses, and immunomodulating
activity from a phytotherapist’s perspective. In Echinacea The
Genus Echinacea; Miller, S., Ed.; CRC Press: Boca Raton, FL,
2004; pp 39, 203-213.
(21) Barnes, J.; Anderson, L.; Gibbons, S.; Phillipson, J. Echinacea
species (Echinacea angustifolia (DC.) Hell., Echinacea pallida
(Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of
their chemistry, pharmacology and clinical properties. J. Pharm.
Pharmacol. 2005, 57, 929-954.
Echinacea Extracts Inhibit Prostaglandin E2 Production J. Agric. Food Chem., Vol. 55, No. 18, 2007 7321
(22) Aparecida Resende, F.; de Andrade Barcala, C.; da Silva Faria,
M.; Kato, F.; Cunha, W.; Tavares, D. Antimutagenicity of ursolic
acid and oleanolic acid against doxorubicin-induced clastogenesis
in Balb/c mice. Life Sci. 2006, 79, 1268-1273.
(23) Senchina, D.; Wu, L.; Flinn, G.; Konopka, D.; Widrelechner,
M.; Wurtele, E.; Kohut, M. Year-and-a-half old, dried Echinaea
roots retain cytokine-modulating capabilities in an in vitro human
older adult model of influenza vaccination. Planta Med. 2006,
72, 1207-1215.
(24) Bauer, R.; Remiger, P. TLC and HPLC analysis of alkamides
in Echinacea drugs. Planta Med. 1989, 55, 367-371.
(25) Dunnett, C. W. A multiple comparison procedure for comparing
several treatments with a control. J. Am. Stat. Assoc. 1955, 50,
1096-1121.
(26) Yu, H.; Kaarlas, M. Popularity, diversity, and quality of
Echinacea. In Echinacea The Genus Echinacea; Miller, S., Ed.;
CRC Press: Boca Raton, FL, 2004; pp 39, 127-149.
(27) Woelkart, K.; Xu, W.; Pei, Y.; Makriyannis, A.; Picone, R.;
Bauer, R. The endocannabinoid system as a target for alkamides
from Echinacea angustifolia roots. Planta Med. 2005, 71, 701-
705.
(28) Raduner, S.; Majewska, A.; Chen, J.; Xie, X.; Hamon, J.; Faller,
B.; Altmann, K.; Gertsch, J. Alkylamides from Echinacea are a
new class of cannabinomimetics: cannabinoid type 2 receptor-
dependent and -independent immunomodulatory effects. J. Biol.
Chem. 2006, 20, 14192-14206.
(29) Gertsch, J.; Schoop, R.; Kuenzle, U.; Suter, A. Echinacea
alkylamides modulate TNF-R gene expression via cannabinoid
receptor CB2 and multiple signal transduction pathways. FEBS
Lett. 2004, 577, 563-569.
(30) McGregor, R. The taxonomy of the genus Echinacea (Com-
positae). UniV. Kans. Sci. Bull. 1968, No. 48, 113-142.
(31) Matthias, A.; Blanchfield, J.; Penman, K.; Toth, I.; Lang, C.;
De Voss, J.; Lehmann, R. Permeability studies of alkylamides
and caffeic acid conjugates from Echinacea using a Caco-2 cell
monolayer model. J. Clin. Pharm. Ther. 2004, 29, 7-13.
(32) Jager, H.; Meinel, L.; Dietz, B. Transport of alkamides from
Echinacea species though Caco-2 monolayers. Planta Med. 2002,
68, 469-471.
(33) Matthias, A.; Gillam, E.; Penman, K.; Matovic, N.; Bone, K.;
De Voss, J.; Lehmann, R. Cytochrome P450 enzyme-mediated
degradation of Echinacea alkylamides in human liver mi-
crosomes. Chem. Biol. Interact. 2005, 165, 62-70.
(34) Woelkart, K.; Koidl, C.; Grisold, A.; Gangemi, J.; Turner, R.;
Marth, E.; Bauer, R. Bioavailability and pharmacokinetics of
alkamides from the roots of Echinacea angustifolia in humans.
J. Clin. Pharmacol. 2005, 45, 683-689.
(35) Matthias, A.; Addison, R.; Penman, K.; Dickinson, R.; Bone,
K.; Lehmann, R. Echinacea alkamide disposition and pharma-
cokinetics in humans after tablet ingestion. Life Sci. 2005, 77,
2018-2029.
Received for review December 21, 2006. Revised manuscript received
June 18, 2007. Accepted June 21, 2007. This research was made possible
by Grant P01 ES012020 from the National Institute of Environmental
Health Sciences (NIEHS) and the Office of Dietary Supplements (ODS),
NIH, and by Grant 95P50AT004155 from the National Center of
Complementary and Alternative Medicine (NCCAM) and ODS, NIH.
Its contents are solely the responsibility of the authors and do not
necessarily represent the official views of the ODS, NIEHS, NCCAM,
or NIH.
JF063711A
7322 J. Agric. Food Chem., Vol. 55, No. 18, 2007 LaLone et al.
